Pressmeddelanden från Hamlet BioPharma

Kommuniké från årsstämma i Hamlet BioPharma AB

Kommuniké från årsstämma i Hamlet BioPharma AB

Hamlet BioPharma Participates in the BioStock Life Science Summit 2024

Hamlet BioPharma Participates in the BioStock Life Science Summit 2024

Q1 Interim Report July 2024 – September 2024

Q1 Interim Report July 2024 – September 2024

Hamlet BioPharma bjuder in till pressträff den 18 november

Hamlet BioPharma bjuder in till pressträff den 18 november

Hamlet BioPharma will present at the BioStock Life Science Summit, November 20

Hamlet BioPharma will present at the BioStock Life Science Summit, November 20

Hamlet BioPharma presenterar på BioStock Life Science Summit 20 november

Den sjunde upplagan av BioStock Life Science Summit går av stapeln 20-21 november, i Lund.

Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website

Hamlet BioPharma, ticker HAMLET B, the innovative pharmaceutical company, which develops new therapies against cancer and infections, is ple...

Rättelse: Hamlet BioPharma AB publicerar årsredovisning 2023/2024

Årsredovisning med koncernredovisning och revisionsberättelse som publicerades tidigare idag saknade uppgift om revisorns utlåtande i pressm...

Hamlet BioPharma publicerar årsredovisning 2023/2024

Hamlet BioPharma publicerar årsredovisning 2023/2024

Kallelse till årsstämma i Hamlet BioPharma AB

Aktieägarna i Hamlet BioPharma AB (”Bolaget”), org.

Immunterapi som behandling av återkommande urinvägsinfektioner – nu tre framgångsrika Fas II studier i Hamlet BioPharm

Immunterapi som behandling av återkommande urinvägsinfektioner – nu tre framgångsrika Fas II studier i Hamlet BioPharm

Hamlet BioPharmas digitala investerarmöte tidigareläggs till den 9 oktober kl. 12:00 CET

Hamlet BioPharmas digitala investerarmöte tidigareläggs till den 9 oktober kl.

Positive Phase II study shows similar clinical outcomes of immunotherapy and antibiotic treatment for recurrent acute cystitis, potentially reducing the need for antibiotics

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections - has successfu...

Hamlet BioPharma bjuder in till digitalt investerarmöte den 18 september kl. 12:00

Hamlet BioPharma bjuder in till digitalt investerarmöte den 18 september kl.

The Economist features groundbreaking research on human breast milk and the story of HAMLET

The Economist features groundbreaking research on human breast milk and the story of HAMLET

Alpha1H treatment shows strong effects in patients with bladder cancer in final analysis published in Cancer Medicine

Alpha1H treatment shows strong effects in patients with bladder cancer in final analysis published in Cancer Medicine

Year-end Report (Q4) July 2023 – June 2024

Year-end Report (Q4) July 2023 – June 2024

Hamlet BioPharma bjuder in till pressträff den 28 augusti

Hamlet BioPharma bjuder in till pressträff den 28 augusti

Invitation to monthly digital events and presentations of quarterly reports

Invitation to monthly digital events and presentations of quarterly reports

Hamlet BioPharma, det innovativa läkemedelsbolaget, med en stark portfölj av projekt för behandling av cancer och infektioner, meddelar uppdatering kring pågående kliniska studier

Hamlet BioPharma, det innovativa läkemedelsbolaget, med en stark portfölj av projekt för behandling av cancer och infektioner, meddelar uppd...

Hamlet BioPharma, the innovative pharmaceutical company, with a strong portfolio of projects, for the treatment of cancer and infections, is featured in this weekend issue of The Guardian

Hamlet BioPharma, the innovative pharmaceutical company, with a strong portfolio of projects, for the treatment of cancer and infections, is...

Hamlet BioPharma Participates in The Global Forum 2024

Hamlet BioPharma Participates in The Global Forum 2024

Q3 Interim Report January - March 2024

Q3 Interim Report January - March 2024

Hamlet BioPharma bjuder in till investerarträff

Hamlet BioPharma bjuder in till investerarträff

Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option

Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option

Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group

Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured co...

Alpha1H to be the first asset for the commercial collaboration

Alpha1H to be the first asset for the commercial collaboration

Analys av immunsvar hos patienter behandlade med Alpha1H publiceras i tidskriften Cancer Medicine

Analys av immunsvar hos patienter behandlade med Alpha1H publiceras i tidskriften Cancer Medicine

Immune responses in patients treated with Alpha1H - results published in the journal Cancer Medicine

Immune responses in patients treated with Alpha1H - results published in the journal Cancer Medicine

Hamlet BioPharma arranges a new series of digital events

Hamlet BioPharma arranges a new series of digital events

Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024

Hamlet BioPharma Participates in Økonomisk Ugebrev’s Life Science Investor Konference 2024

Hamlet BioPharma Participates in Swiss Nordic Bio 2024

Hamlet BioPharma Participates in Swiss Nordic Bio 2024

Hamlet BioPharma meddelar sista dag för handel med BTA

Hamlet BioPharma meddelar sista dag för handel med BTA

Q2 Interim Report October - December 2023

Q2 Interim Report October - December 2023

Hamlet BioPharma bjuder in till pressträff

Hamlet BioPharma bjuder in till pressträff

Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances

Hamlet BioPharma Enters Commercial Collaborations with Top International Advisory Firms to Enhance Partnering and Strategic Alliances

Hamlet BioPharma AB meddelar att bolaget genom företrädesemission tillförs totalt cirka 46,7 MSEK före avdrag för emissionskostnader

Hamlet BioPharma AB meddelar att bolaget genom företrädesemission tillförs totalt cirka 46,7 MSEK före avdrag för emissionskostnader

Storbankerna har kortat ner teckningstiden – du kan fortfarande teckna direkt

Storbankerna har kortat ner teckningstiden – du kan fortfarande teckna direkt

New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effects

New analyses of clinical data from Alpha1H treated patients with bladder cancer detect a strong immune response with known anti-tumor effect...

Nya analyser av kliniska data från Alpha1H-behandlade patienter med cancer i urinblåsan

Nya analyser av kliniska data från Alpha1H-behandlade patienter med cancer i urinblåsan

Hamlet BioPharmas styrelse, ledning och rådgivare deltar i företrädesemissionen

Hamlet BioPharmas styrelse, ledning och rådgivare deltar i företrädesemissionen

Hamlet BioPharma inbjuder till digitala investerarmöten

Hamlet BioPharma inbjuder till digitala investerarmöten

Rättelse:Hamlet BioPharma AB offentliggör prospekt i samband med företrädesemission

Pressmeddelandet har nu korrigerats genom att ta bort MAR etiketten.

Hamlet BioPharma AB offentliggör prospekt i samband med företrädesemission

Hamlet BioPharma AB offentliggör prospekt i samband med företrädesemission

Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024

Hamlet BioPharma featured at MSQ’s CEO Webinar series released during the JP Morgan Health Care Conference 2024

Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains

Immunotherapy - a new approach to treating bacterial infections, including antibiotic resistant strains

Antimicrobial peptide therapy for tuberculosis infections

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer...

Kommuniké från årsstämma i Hamlet BioPharma AB

Kommuniké från årsstämma i Hamlet BioPharma AB

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB

Kommuniké från extra bolagsstämma i Hamlet BioPharma AB

Hamlet BioPharma Announces the Nomination of Elisabeth Parker to its Board of Directors

Hamlet BioPharma Announces the Nomination of Elisabeth Parker to its Board of Directors

Hamlet BioPharma is inviting you to join a digital presentation at Invest Live, Tuesday December 12[th] at 12.00 CET

Hamlet BioPharma is inviting you to join a digital presentation at Invest Live, Tuesday December 12[th] at 12.

Hamlet BioPharma’s continued development of brain tumor therapy

Hamlet BioPharma’s continued development of brain tumor therapy

Hamlet BioPharma receives U.S. FDA Fast Track designation for Alpha 1H for the treatment of non-muscle invasive bladder cancer

Lund, Sweden, November 29, 2023. Hamlet BioPharma AB (publ), the pharmaceutical company with a strong portfolio of projects for the treatmen...

Kallelse till extra bolagsstämma i Hamlet BioPharma AB

Kallelse till extra bolagsstämma i Hamlet BioPharma AB

Hamlet BioPharma AB föreslår företrädesemission av B-aktier med möjlighet att säkra cirka 40MSEK. Cirka 13MSEK har tecknats i förhand via teckningsförbindelser. Tekniskt uppgår emissionen till 80MSEK

Hamlet BioPharma AB föreslår företrädesemission av B-aktier med möjlighet att säkra cirka 40MSEK.

Hamlet BioPharma publicerar årsredovisning 2022/2023

Hamlet BioPharma publicerar årsredovisning 2022/2023

Q1 Interim report July - September 2023

Q1 Interim report July - September 2023

Kallelse till årsstämma i Hamlet BioPharma AB

Aktieägarna i Hamlet BioPharma AB (”Bolaget”), org.

Newsletter from Hamlet Biopharma

Newsletter from Hamlet Biopharma

Hamlet BioPharma presented at the FS Market event on October 25th

Hamlet BioPharma presented at the FS Market event on October 25th

Bolagsstämma för Hamlet BioPharma planeras äga rum den 14 december 2023

Bolagsstämma för Hamlet BioPharma planeras äga rum den 14 december 2023

Prof. Gabriela Godaly will present valuable insights into the pressing global issues of tuberculosis and antibiotic resistance at the 178th Nobel Symposium in Chemistry in Stellenbosch, South Africa

Professor Gabriela Godaly is working with Hamlet BioPharma  to develop  a new therapeutic concept to combat tuberculosis through the use of ...

Strong anti-tumor effects detected in Alpha1H treated patients, for a combination of clinical and molecular endpoints

Hamlet BioPharma, the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces the r...

Ändrad tid för investerarmöte i Hamlet BioPharma AB

Ändrad tid för investerarmöte i Hamlet BioPharma AB

Martin Erixon återinträder som VD

Martin Erixon återinträder som VD

Hamlet BioPharma håller digitalt investerarmöte

Hamlet BioPharma håller digitalt investerarmöte

Hamlet BioPharma will be presenting at Aktiedagen, Aktiespararna, on Monday, October 9th, in Lund at 12:10 CET

Hamlet BioPharma will be presenting at Aktiedagen, Aktiespararna, on Monday, October 9th, in Lund at 12:10 CET

Önskar du som aktieägare i Hamlet BioPharma AB information från bolaget via e-post?

Önskar du som aktieägare i Hamlet BioPharma AB information från bolaget via e-post?

Hamlet Pharma Year-end Report July 2022 – June 2023

Hamlet Pharma Hamlet Pharma is developing an entirely new class of anti-cancer therapeutics for multiple cancer indications based on the di...

Hamlet Pharma AB (publ) genomför namnbyte till Hamlet BioPharma AB (publ)

Hamlet Pharma AB (publ) genomför namnbyte till Hamlet BioPharma AB (publ)

Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB

Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB

Bolagsverket meddelar tillstånd till fusion mellan Hamlet Pharma AB (publ) och SelectImmune Pharma AB (publ)

Bolagsverket meddelar tillstånd till fusion mellan Hamlet Pharma AB (publ) och SelectImmune Pharma AB (publ)

Kallelse till extra bolagsstämma i Hamlet Pharma AB (publ)

Aktieägarna i Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”), 556568-8958, kallas härmed till extra bolagsstämma onsdagen den 11 ...

FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer

FDA Clearance of IND Application for Alpha1H for the treatment of non-muscle invasive bladder cancer

Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma

Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infection and ...

Hamlet Pharma secures long-term Alpha1 peptide production in an agreement with Polypeptide Group

Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of p...

Hamlet Pharma soon to be Hamlet BioPharma presents at Aktiespararnas Capital Market Day on June 12 in Stockholm at 13.30 CET

Lund, June 9, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the t...

Teckningsoptioner av serie TO 4 B tecknades till cirka 38% procent och Hamlet Pharma AB (publ) tillförs cirka 3,5 MSEK

Teckningsoptioner av serie TO 4 B tecknades till cirka 38% procent och Hamlet Pharma AB (publ) tillförs cirka 3,5 MSEK

Hamlet Pharma secures a new Alpha1H production batch for continued clinical trials

Lund, May 31, Hamlet Pharma soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the t...

Sista dag i utnyttjandeperioden för teckningsoptioner av serie TO 4 B i Hamlet Pharma AB (publ) är imorgon, den 31 maj 2023

Sista dag i utnyttjandeperioden för teckningsoptioner av serie TO 4 B i Hamlet Pharma AB (publ) är imorgon, den 31 maj 2023

Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023

Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023

Introducing Hamlet BioPharma to investors

Introducing Hamlet BioPharma to investors

Kommuniké Från Extra Bolagsstämman i Hamlet Pharma AB

Vid extra bolagsstämma i Hamlet Pharma AB, org.nr. 556568-8958, (”Hamlet Pharma” eller ”Bolaget”) den 17 maj 2023 fattades följande beslut.

Teckningskurs för utnyttjande av teckningsoptioner serie TO 4 B i Hamlet Pharma AB (Publ) har fastställts till 2,32 SEK per aktie

Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”) emitterade under 2021 teckningsoptioner av serie TO 4 B.

Hamlet Pharma achieves full funding from the European Commission

In a recent evaluation of Hamlet Pharma, the European Commission concluded that Hamlet Pharma’s bladder cancer project has delivered excepti...

Kallelse till extra bolagsstämma i Hamlet Pharma AB (publ)

Aktieägarna i Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”), org.

Notice of extraordinary general meeting in Hamlet Pharma AB (publ)

The shareholders of Hamlet Pharma AB (publ) (“Hamlet Pharma” or the “Company”), reg.

Hamlet Pharma & SelectImmune Pharma invites to a digital investor meeting on April 3rd and April 4th at 12.00 CET

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for...

Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections

This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zea...

Hamlet Pharma och SelectImmune Pharma går samman för att skapa ett nydanande läkemedelsbolag med en bred och stark portfölj av projekt för behandling av cancer och infektioner

Detta pressmeddelande eller fusionen utgör inte ett erbjudande, vare sig direkt eller indirekt i Australien, Hongkong, Japan, Kanada, Nya Ze...

Hamlet Pharma AB: Hamlet Pharma Q2 Interim Report October 2022 – December 2022

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for...

Hamlet Pharma holds a digital investor meeting

Hamlet Pharma is inviting you to a digital investors’ meeting via Zoom, on Wednesday 30th November at 12.

Hamlet Pharma Q1 Interim Report July 2022 – September 2022

Opening remarks The HAMLET family of drug candidates has remarkable effects and continues to show great promise for the prevention and trea...

BAMLET in the drinking water; protection against intestinal cancer and potent beneficial health effects

Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone.

Hamlet Pharma AB (publ): Hamlet Pharma publicerar årsredovisning 2021/2022

Kallelse till årsstämma i Hamlet Pharma AB (publ)

Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 24 november 2022 kl.

Hamlet Pharma Year-end Report July 2021 – June 2022

Opening remarks The fiscal year 2021/2022 of Hamlet Pharma AB has been very successful and important milestones have been reached.

Hamlet Pharma får nytt snabbt godkännande i Tjeckien

Läkemedelsmyndigheten i Tjeckien har snabbt godkänt ansökan från Hamlet Pharma om utökad klinisk prövning av Alpha1H

Full fart framåt! – Hamlet Pharma utvecklar det kliniska prövningsprogrammet ytterligare

Hamlet Pharma utvecklar nya läkemedelskandidater med målet att behandla olika former av cancer utan att orsaka allvarliga biverkningar.

Full speed ahead! – Hamlet Pharma adapts the clinical trial program for stand-alone use

Hamlet Pharma develops new drug candidates to treat cancer without causing significant side effects.